Solifenacin: Uses, Side Effects, Dosing & Alternatives

Solifenacin is a prescription medication used to treat overactive bladder, a condition marked by frequent urination, sudden urges to urinate, and sometimes involuntary urine leakage. Sold under the brand name Vesicare, it belongs to a class of drugs called antimuscarinics, which work by calming the muscle that controls the bladder. Clinical trials have consistently shown that both the 5 mg and 10 mg daily doses significantly reduce all major overactive bladder symptoms compared to placebo, and the drug has been a mainstay of treatment since its approval in 2004.

How Solifenacin Works

Your bladder muscle contracts when a chemical messenger called acetylcholine binds to receptors on its surface, specifically a subtype known as M3 muscarinic receptors. Solifenacin blocks those receptors, which reduces involuntary bladder contractions and lets the bladder hold more urine before you feel the urge to go. What makes solifenacin somewhat distinctive among overactive bladder drugs is its selectivity for the M3 receptor. In laboratory binding studies, solifenacin showed higher affinity for M3 receptors than for the M1 and M2 subtypes.¹

That selectivity matters because M3 receptors are also found in the salivary glands, and blocking them there is what causes dry mouth, the most familiar side effect of this entire drug class. Studies comparing solifenacin with oxybutynin, an older antimuscarinic, in knockout mice found that solifenacin binds more selectively to M3 receptors in the bladder compared to those in the salivary glands, while oxybutynin does not show that preference.² Research in primate cells confirmed this pattern: solifenacin’s selectivity index for bladder over salivary gland tissue was roughly four times higher than that of oxybutynin, tolterodine, or darifenacin.³ In practice, this translates to a somewhat better side-effect profile, though dry mouth still occurs.

Once you swallow a tablet, solifenacin is processed mainly through the liver by the CYP3A4 enzyme system. Only about 7% of the dose is cleared unchanged by the kidneys. Its elimination half-life ranges from roughly 33 to 85 hours, which is long enough to allow once-daily dosing and means the drug builds to a steady level in the body over several days.⁴

What the Clinical Trials Show

Across multiple randomized, double-blind trials, solifenacin at both 5 mg and 10 mg daily has significantly improved all major overactive bladder symptoms: urinary frequency, urgency, and incontinence episodes.⁵ In one large trial that included tolterodine as an active comparator, solifenacin 10 mg reduced the average number of daily voids by about 20% compared to a roughly 8% drop with placebo. Both solifenacin doses produced a statistically significant decrease in incontinence episodes, while the reduction with tolterodine in that trial did not quite reach statistical significance.⁶

Beyond symptom counts, solifenacin also improves quality of life. Pooled data from two 12-week trials totaling nearly 1,900 patients showed statistically significant improvements over placebo in nine out of ten quality-of-life domains measured. Patients who continued on the drug in an extension phase saw additional quality-of-life gains beyond the initial 12 weeks.⁷ These results hold whether or not urgency is the dominant symptom: a comparative study found that patients with urinary frequency alone experienced similar reductions in daily voiding episodes as those who also had urgency.⁸

Side Effects You Should Know About

The most common side effects are dry mouth and constipation.⁹ These are class-wide effects of antimuscarinic drugs, and while solifenacin’s bladder selectivity helps reduce their intensity compared to some older alternatives, they still bother a meaningful number of patients. The constipation is pharmacologically predictable: M3 receptors line the gut wall, and blocking them slows bowel motility.¹⁰ Other possible side effects include blurred vision, urinary retention (difficulty fully emptying the bladder), and, less commonly, effects on heart rhythm.

Solifenacin can block cardiac potassium channels, which raises the possibility of QT interval prolongation, a change in the heart’s electrical activity that in rare cases can lead to dangerous arrhythmias. This risk is heightened if you are also taking other QT-prolonging medications, drugs that inhibit the CYP3A4 enzyme, or if you have low potassium or magnesium levels.¹¹ Your prescriber should review your other medications and electrolyte status before starting you on solifenacin, especially if you have a history of heart rhythm problems.

Solifenacin and the Brain

Anticholinergic drugs as a class have come under scrutiny for possible effects on cognition, particularly in older adults. Solifenacin can cross the blood-brain barrier and interact with M1 receptors in the brain, which are involved in memory and learning. Short-term clinical studies have generally found solifenacin to be safe for cognition, but there are no long-term randomized trials proving the drug has no effect on the brain over extended use.¹²

The concern is not purely theoretical. A large nested case-control study using the French national medical database found that use of anticholinergic overactive bladder drugs was associated with roughly a 23% increased risk of dementia. The risk rose with cumulative exposure: people who had taken higher total doses over time showed a 48% increased risk. When the researchers looked at individual drugs, oxybutynin and solifenacin stood out as having particularly elevated dementia risk, while trospium, which does not cross the blood-brain barrier, showed no increased risk.¹³ This was observational research, not a randomized trial, so it cannot prove that solifenacin directly causes dementia. But given the dose-response pattern, many clinicians now advise caution with prolonged solifenacin use in elderly patients.

How It Stacks Up Against Alternatives

Solifenacin is one of several antimuscarinic drugs available for overactive bladder, alongside tolterodine, oxybutynin, darifenacin, fesoterodine, and propiverine. There is also mirabegron, which works through an entirely different mechanism (activating beta-3 receptors on the bladder muscle rather than blocking muscarinic receptors).

A network meta-analysis comparing solifenacin 5 mg to other antimuscarinics found it significantly more effective than tolterodine 4 mg for reducing incontinence and urgency-related incontinence episodes. At the same time, solifenacin 5 mg had significantly lower dry mouth rates than darifenacin 15 mg, fesoterodine 8 mg, oxybutynin at higher doses, and even the 10 mg dose of solifenacin itself.¹⁴ A separate systematic review found that solifenacin 5 mg significantly improved incontinence and urgency compared to tolterodine 4 mg, with similar rates of treatment dropout due to side effects.¹⁵

Compared to mirabegron, the picture is more nuanced. A meta-analysis of head-to-head trials found no significant differences in incontinence episodes, daily voiding frequency, urgency episodes, or voided volume between the two drugs. However, mirabegron showed better tolerability, with fewer drug-related side effects and less dry mouth.¹⁶ A randomized trial looking at cardiovascular effects found that solifenacin modestly lowered blood pressure while mirabegron slightly increased heart rate, but neither drug had a significant impact on autonomic function or arterial stiffness after 12 weeks.¹⁷ For patients who cannot tolerate antimuscarinics or who are concerned about the cognitive risks mentioned earlier, mirabegron is a reasonable alternative. In children, a meta-analysis found no significant difference in treatment response between mirabegron and solifenacin, but mirabegron was associated with significantly fewer adverse events.¹⁸

Dosing and Dose Escalation

Solifenacin comes in 5 mg and 10 mg tablets, taken once daily with or without food. Prescribers typically start at 5 mg, which is enough for many patients. Phase 2 dose-finding work identified 5 mg and 10 mg as the sweet spot, balancing efficacy, quality of life, and tolerability.¹⁹

If symptoms remain bothersome after several weeks at 5 mg, stepping up to 10 mg often helps. The SUNRISE trial showed that patients with more severe symptoms who requested a dose increase after eight weeks on 5 mg experienced further improvement when moved to 10 mg.²⁰ The trade-off is that higher doses tend to bring more side effects, especially dry mouth. In people who have previously tried tolterodine extended-release and found it insufficient, switching to solifenacin with the option to escalate from 5 to 10 mg has also been studied, with symptom improvements emerging by week four.²¹

Drug Interactions to Watch For

Because solifenacin is metabolized primarily by the CYP3A4 liver enzyme, anything that strongly inhibits that enzyme can raise solifenacin levels in your blood. In a study of healthy volunteers, co-administration with ketoconazole, a potent CYP3A4 inhibitor, roughly doubled solifenacin’s overall exposure and extended its half-life from about 49 hours to nearly 78 hours.²² Other strong CYP3A4 inhibitors include certain antifungals like itraconazole, some HIV protease inhibitors, and clarithromycin. If you take any of these regularly, your doctor may need to adjust the solifenacin dose or consider an alternative bladder medication. Grapefruit juice is a milder CYP3A4 inhibitor and is less likely to cause a clinically meaningful interaction, but large quantities are still worth mentioning to your prescriber.

The cardiac rhythm concern noted earlier also creates interaction potential. Taking solifenacin alongside other QT-prolonging medications, some antiarrhythmics, certain antipsychotics, or specific antibiotics, raises the combined risk of heart rhythm disturbances. Low potassium or magnesium amplifies this risk further.

How Long People Actually Stay on It

One of the underappreciated challenges with overactive bladder medication is that many people stop taking it within a year, regardless of which drug they start. In a prospective cohort study, only 40% of patients were still taking solifenacin after 12 months, with about half having discontinued. The main reasons were lack of efficacy (39% of discontinuations), side effects (30%), or both (13%).²³ A Japanese study of previously untreated women found similar numbers: about 41% still on the drug at one year, dropping to roughly 23% at three years. Interestingly, symptom resolution was a leading reason for stopping in that cohort, accounting for about 27% of discontinuations.²⁴

A head-to-head persistence trial comparing solifenacin with mirabegron in women found that solifenacin had a slightly higher 12-month persistence rate (about 20% versus 12% for mirabegron), though the difference was not statistically significant. The reasons people quit differed, though: discontinuation due to side effects was significantly more common with solifenacin, while discontinuation due to lack of efficacy was significantly more common with mirabegron.²⁵ The takeaway: if solifenacin works for you, there is a decent chance side effects will be the reason you stop. If mirabegron works, the side-effect burden may be lighter, but you might find it less effective.

Neurogenic Bladder and Pediatric Use

Solifenacin is not only used for typical overactive bladder. People with neurogenic detrusor overactivity, where spinal cord injury, multiple sclerosis, or other neurological conditions cause the bladder to contract uncontrollably, also benefit from the drug. A study of patients with spinal cord lesions found that solifenacin significantly increased bladder capacity, improved detrusor compliance, and lowered maximum bladder pressure over a median follow-up of about 13 months.²⁶ The randomized, placebo-controlled SONIC trial confirmed these findings: solifenacin 10 mg significantly improved bladder capacity and quality of life in patients with neurogenic overactivity due to multiple sclerosis or spinal cord injury after just four weeks.²⁷

In children, solifenacin is available as an oral suspension for patients aged six months to 18 years with neurogenic detrusor overactivity. Two phase 3 open-label studies showed significant increases in bladder capacity after 24 weeks of treatment in both younger children (under 5) and older children, along with reduced incontinence episodes and improved bladder compliance. Side effects were mostly mild to moderate and resembled the profile seen in adults.²⁸

Combination With Tamsulosin for Men

Many men with an enlarged prostate experience a blend of obstructive symptoms (weak stream, straining) and overactive bladder symptoms (urgency, frequency). Alpha-blockers like tamsulosin address the obstructive component, but they don’t do much for urgency. Adding solifenacin to tamsulosin targets both issues. A trial of this combination found that all subjective and objective measures, including daytime and nighttime voiding frequency, urgency episodes, and quality of life, improved significantly more with the combination than with tamsulosin alone.²⁹

The NEPTUNE trial tested a fixed-dose combination tablet of solifenacin 6 mg with tamsulosin. It found improvements in symptom scores and patient-reported urgency compared with tamsulosin alone and placebo, with low rates of acute urinary retention, a common worry when adding an antimuscarinic in men with enlarged prostates.³⁰ This combination tablet (marketed as Vesomni in some countries) is a practical option for men dealing with both conditions who want to avoid taking multiple pills.

What It Costs Relative to Other Options

Cost-effectiveness analyses have generally been favorable for solifenacin, though the specifics depend on the country and the comparator drug. A Canadian analysis found that solifenacin was cost-effective compared to oxybutynin immediate-release, with an incremental cost per quality-adjusted life year well below the typical willingness-to-pay threshold, and it remained cost-effective in over 90% of simulated scenarios.³¹ A UK analysis found solifenacin dominant (meaning cheaper and more effective) compared to fesoterodine and both forms of tolterodine, though it was not cost-effective relative to generic oxybutynin for frequency and incontinence outcomes.³²

In the United States, an analysis from the payer perspective found incremental costs per quality-adjusted life year of roughly $45,000 for solifenacin compared to fesoterodine, making it cost-effective in about 77% of simulated cases at a $50,000 threshold.³³ These numbers shift depending on whether generic versions are available in a given market and whether costs like incontinence pads are factored in. The broader point is that solifenacin generally offers good value relative to branded competitors, though the cheapest option on paper will usually be generic oxybutynin, which comes with more side effects and the cognitive concerns discussed earlier.